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Background: PRO2000/ANCCA may be an important candidate gene which located within a region of
chromosome 8q in hepatocellular carcinoma (HCC). However, its significance remains unclear. The aim of this study
was to explore the clinical significance of PRO2000/ANCCA expression in HCC.
Methods: The correlations of PRO2000/ANCCA expression with clinicopathological factors and prognosis of HCC
patients were analyzed. Expression of PRO2000/ANCCA, ki-67, cyclinD1, p53 and p21 was detected in HCCs from
107 patients along with corresponding non-tumor tissues by immunohistochemistry.
Results: PRO2000/ANCCA expression was present in 66 of 107 (64.94%) HCC specimens in which 36 of 76 (47.37%)
in well differentiated tumors and 30 of 31 (96.77%) in poorly differentiated tumors respectively, while 8 (7.48%)
in adjacent non-tumor tissues with scattered positive cells. PRO2000/ANCCA expression was associated with
clinicopathological features such as histological differentiation, number of tumor nodules, TNM stage, tumor
microsatellite, portal vein tumor thrombus and recurrence, but not with gender, age, tumor size, cirrhosis, HBV
infection and serum fetoprotein (AFP) level. There was a close relationship between PRO2000/ANCCA and ki-67 and
cyclinD1 in HCC. PRO2000/ANCCA immunopositivity was independent of p53 and p21WAF1/Cip1.
Conclusions: Increased expression of PRO2000/ANCCA is associated with adverse outcome in patients with HCC
and is a predictor of poor prognosis for HCC. PRO2000/ANCCA may be involved in the development of HCC and
might promote cell proliferation through a p53/ P21WAF1/Cip1-independent pathway.
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Primary hepatocellular carcinoma (HCC), is the fifth most
common cancer worldwide and the third most common
cause of cancer-related mortality with approximately
696,000 deaths each year. More than 50% of the world-
wide cases of HCC occur in China, because of the high
prevalence of chronic hepatitis B virus infection and liver
cirrhosis [1,2]. A detailed understanding of the molecular
mechanisms associated with HCC ultimately could im-
prove our current diagnosis and treatments for this dis-
ease. Throughout the years, many important advances
have been made to understand the pathogenesis of HCC.* Correspondence: linlangg@yahoo.com
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unless otherwise stated.A subset of cytogenetic changes, including frequent gain
of chromosome 8q which the most commonly amplified
region in multiple cancer types were found to be involved
in the early development of HCC by comparative genomic
hybridization (CGH) and comparative genomic microarray
analysis (CGMA). PRO2000/ANCCA, one of the genes on
chromosome 8q was highly expressed (4.7 folds) in HCC
comparing to corresponding non-cancerous samples and
showed a high correlation between DNA copy number
and expression levels in HCC samples. The data suggested
that PRO2000/ANCCA may be an important candidate
gene in the development of HCC [3].
PRO2000, a novel member of the AAA + superfamily,
has been also named as ANCCA (AAA nuclear coregula-
tor cancer-associated protein) or ATAD2 (AAA domain
containing 2) or TAAB (ACTR target with AAA + ATPased. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological correlation of PRO2000/





Male 96 38 46 12
Female 11 3 6 2
Age (years) 0.524
≤51 53 23 23 7
>51 54 18 29 7
Serum HBsAg 0.737
Negative 44 17 20 7
Positive 63 24 32 7
Serum AFP (ng/ml) 0.703
≤20 48 18 25 5
>20 59 23 27 9
Tumor size (cm) 0.107
≤5 55 25 26 4
>5 52 16 26 10
Tumor number 0.003
Single 80 38 32 10
Multiple 27 3 20 4
Tumor differentiation <0.001
I-II 76 40 34 2
III-IV 31 1 18 12
Cirrhosis 0.519
Negative 51 21 22 8
Positive 56 20 30 6
TNM stage <0.001
I-II 81 41 38 2
III-IV 26 0 14 12
Tumor microsatellite 0.011
Absent 77 36 31 10




Absent 96 41 47 8
Present 11 0 5 6
Recurrence <0.001
Absent 89 39 43 7
Present 18 2 9 7
-, negative; +, moderate positive; ++, strong positive. Significant differences
are shown in bold.
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ANCCA and ATAD2 are the most commonly used names
in the published data, but we prefer to call it PRO2000,
which is the originate name of this gene first discovered in
HCC. PRO2000/ANCCA contains two AAA + domains in
the central region with the first one being crucial for its
transcription coactivator function and a bromodomain
close to the COOH-terminus that specifically recognizes
acetylated histones [5]. Several laboratories have reported
that PRO2000/ANCCA was overexpressed in different
human cancers, including breast cancer, prostate cancer,
lung cancer and endometrial cancer. High levels of
PRO2000/ANCCA was associated with poor prognosis
in cancer patients. These studies showed PRO2000/
ANCCA was involved in the estrogen and androgen
receptor pathways to mediate estrogen- or androgen-
induced expression of specific subsets of proliferation-
associated genes. In addition, PRO2000/ANCCA acts as
an important co-regulator of MYC and contributes to
the development of aggressive cancer [6-13]. However,
the molecular mechanisms of PRO2000/ANCCA lead-
ing to hepatocarcinogenesis and progression are still not
clearly understood.
In this study, we investigated for the first time the
significance of PRO2000/ANCCA expression in HCC.
Protein expression of PRO2000/ANCCA was examined
in relation to clinicopathological features in 107 cases of
HCC by immunohistochemical technique. The relation-
ships between PRO2000/ANCCA expression and ki-67,




One hundred and seven samples were obtained by surgi-
cal resection in our department between January 2004
and June 2008. The patients, 96 males (89.7%) and 11 fe-
males (10.3%), ranged in age from 30 to 79 years (mean
51.45). Tumor sizes were divided as less than or equal to
5 cm (n = 55) and more than 5 cm (n = 52). Tumor stage
was defined according to the 7th edition of the American
Joint Committee on Cancer staging manual. Written in-
formed consent was obtained from all the patients for the
use of the tumor tissues for clinical research and the pub-
lication of this report. The project protocol was approved
by the Institutional Ethics Committee of Zhujiang Hos-
pital prior to the initiation of the study. Clinicopathologi-
cal features of study population were presented in Table 1.
All samples were independently reviewed by two pathol-
ogists. The cases of HCC were classified according to
the criteria described by Edmondso-Steiner and grouped
as well differentiated (gradeI-II; n = 76) or poorly differ-
entiated (grade III-IV; n = 31). All 107 specimens con-
tained pericarcinomatous tissues, in which including 56cases with cirrhosis. Sixty-three patients were seroposi-
tive for HBsAg and HBeAg. No positive case for HCV
was present in this study. All tissues were fixed in 10%
formalin (pH 7.0) for 12–24 hours and embedded in
Figure 1 Immunohistochemical staining of PRO2000/ANCCA protein in human liver tissue samples. (A) HCC tissues and (B) adjacent
non-tumor tissues were immunohistochemically stained with an anti-PRO2000/ANCCA antibody Positive PRO2000/ANCCA immunostaining was
mainly localized in the nucleus of cells. Scale bars = 50 μm.
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mounted on poly-l-lysine coated slides.
Immunohistochemical staining
Sections were deparaffinized and rehydrated routinely.
Before adding the primary antibody, antigen was re-
trieved by heating sections in 10 mM citrate buffer
(pH 6.0) in a microwave oven for 10 minutes followed
by 10 minutes of cooling. After blocking with 0.3% H2O2
and goat serum, the slides were then incubated with a pri-
mary antibody, directed against PRO2000/ANCCA (1:100
dilution, gift from Dr Hongwu Chen’s lab, UCDAVIS, Can-
cer center, USA), ki-67(MIB-1, Dako, Glostrup, Denmark),
cyclin D1(SP4, Dako, Glostrup, Denmark), p53(DO-7,
Dako, Glostrup, Denmark) and p21WAF1/Cip1(4D10, Dako,
Glostrup, Denmark) at 4°C overnight. Biotinylated sec-
ondary antibodies were then applied according to the
manufacturer’s recommendations (Amersham). After
incubation with avidin biotin complex using the Vector
Elite ABC detection kit (Vector Labs, Burlingame, USA),
reaction products were visualized by 3’diaminobenzidine
(DAB), and slides were subsequently counterstained
with hematoxylin. Brown-yellow granules in nucleus orFigure 2 Kaplan-Meier analyses of overall survival (A) and disease-fre
expression. –, negative; +, moderate positive; ++, strong positive.cytoplasm were considered positive staining. The posi-
tive reactivity was scored semiquantitatively by micro-
scopic evaluation according to the estimated number of
positive nuclei or cytoplasm of target cells. The scores
were graded into four groups from 0 to 3+ as follow : 0,
no positive cells; +, less than 25% of positive cells; 2+,
25-50% of positive cells; and 3+, >50% of positive cells.
Negative controls were performed by replacing the pri-
mary antibodies stated above with PBS. The specimens
were classified according to IHC staining scores of
PRO2000/ANCCA as negative group (−, n = 41), moder-
ate positive group (+, n = 52), strong positive group
(++, n = 14).Statistical analysis
Correlation of PRO2000/ANCCA expression with clinical
features, and expression of ki-67, cyclin D1, p53 and
p21WAF1/Cip1 was calculated by χ2 test. Survival curves
were obtained by Kaplan-Meier analysis. In all cases, a
P value <0.05 was considered to indicate statistical signifi-
cance. Statistical analysis was performed using the SPSS
software program 17.0 (SPSS Inc., Chicago, IL, USA).e survival (B) in 107 HCC patients based on PRO2000/ANCCA
Table 2 Univariate and multivariate analyses of potential prognostic factors associated with overall survival of HCC
patients
Variables Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Gender (male/female) 1.128 (0.602-2.115) 0.707
Age (years) (≤51/>51) 2.305 (1.525-3.484) <0.001 3.570 (2.311-5.516) <0.001
Serum HBsAg (negative/positive) 0.822 (0.556-1.215) 0.326
Serum AFP (ng/ml) (≤20/>20) 0.945 (0.645-1.384) 0.772
Tumor size (cm) (≤5/>5) 1.410 (0.958-2.077) 0.082
Tumor number (single/multiple) 2.250 (1.422-3.559) 0.001 1.149 (0.300-4.403) 0.839
Tumor differentiation (I-II/III-IV) 7.922 (4.739-13.242) <0.001 3.292 (1.563-6.937) 0.002
Cirrhosis (absent/present) 0.999 (0.679-1.471) 0.996
TNM stage (I-II/III-IV) 23.349 (11.008-49.527) <0.001 3.848 (1.494-9.915) 0.005
Tumor microsatellite (absent/present) 1.877 (1.216-2.896) 0.004 1.404 (0.392-5.030) 0.602
Portal vein tumor thrombus (absent/present) 46.801 (16.166-135.495) <0.001 11.741 (3.503-39.355) <0.001
Recurrence (absent/present) 2.739 (1.628-4.609) <0.001 1.220 (0.645-2.308) 0.541
ANCCA expression (−/+/++) 10.275 (6.440-16.395) <0.001 8.745 (4.936-15.493) <0.001
HR: hazard ratio, CI confidence interval. The P-value was calculated by Cox proportional hazards model.
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Expression of PRO2000/ANCCA and its correlation with
clinicopathological characteristics in HCC
Immunohistochemical staining demonstrated a granular
staining pattern of PRO2000/ANCCA in the nucleus of
cancer cells (Figure 1A), whereas few scattered positive cells
were detected in adjacent non-tumor tissues (Figure 1B).
Sixty-six of 107 (61.68%) HCC specimens were presented
positive staining for PRO2000/ANCCA, while 8 (7.48%) in
non-cancer cells. It was positive in 30/31 (96.77%) poorly
differentiated tumors and 36/76 (47.37%) well differentiated
lesions. There was a significantly increased expression of
PRO2000/ANCCA in poorly differentiated tumors than
that in well differentiated tumors (χ2 = 36.736, P < 0.001).
The intensity of PRO2000/ANCCA staining in cancer cells
was much stronger than that in non-cancer cells.Figure 3 Immunohistochemical expressions of ki-67 and cyclin D1 in
(A) ki-67 and (B) cyclinD1 were localized in the nucleus of cancer cell. ScalWe further analyzed the relationship between the ex-
pression of PRO2000/ANCCA and clinicopathological
features of the HCC patients. As shown in Table 1, the
expression of PRO2000/ANCCA was showed significant
correlation with number of tumor nodules, TNM stage,
tumor microsatellite, portal vein tumor thrombus and
recurrence. However, no significant relationship was seen
between PRO2000/ANCCA expression and gender, age,
tumor size, cirrhosis, HBV infection and serum AFP level.
In addition, Kaplan-Meier analysis and log-rank test re-
vealed that high expression of PRO2000/ANCCA was
significantly associated with shorter overall survival
(Figure 2A) and disease-free survival (Figure 2B). Fur-
ther multivariate Cox regression analysis indicated that
PRO2000/ANCCA is an independent prognostic factor
for survival of patients with HCC (P < 0.001, Table 2).consecutive sections of an HCC tissue. Positive immunostaining of
e bars = 50 μm.
Table 3 Relationship between PRO2000/ANCCA and ki-67,
cyclin D1, p53 and p21 in HCC
PRO2000/
ANCCA Cases
ki-67 cyclin D1 p53 p21
+ - + - + - + -
Positive 65 46 19 40 25 29 36 26 39
Negative 42 18 24 9 33 25 17 13 29
χ2 8.270 16.536 2.269 0.902
P-value 0.004 <0.001 0.132 0.342
-, negative; +, positive. Significant differences are shown in bold.
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D1 in HCC
In all 107 cases of HCC, ki-67 and cyclin D1 positive
cells were showed brown staining in the nucleus. In con-
secutive sections of an HCC, PRO2000/ANCCA, Ki-67
and cyclin D1 were showed to be co-expressed in the
same cancer cell within individual tumor (Figure 3).
The correlation between PRO2000/ANCCA and ki-67 or
cyclin D1 is summarized in Table 3. The ki-67 and cyclin
D1 were significantly higher in PRO2000/ANCCA -positive
group than that in PRO2000/ANCCA-negative group
(P < 0.05).Association between PRO2000/ANCCA and p53 or p21 in
HCC
Previous studies and our results showed nuclear staining
for p53 or p21WAF1/Cip1 in HCCs. However, PRO2000/
ANCCA expression was not consistent with p53 or
p21WAF1/Cip1 in cancer cells in consecutive sections of
an HCC (Figure 4). Nuclear immunoreactivity for p53
and p21 was found in 33 (42.86%) and 37 (48.05%)
HCCs respectively. We analyzed the expression level of
PRO2000/ANCCA and p53 and p21WAF1/Cip1 expression
in HCC. Among PRO2000/ANCCA-positive cases, p53
and p21WAF1/Cip1 were expressed in 72.7% and 81.8% in
HCC, respectively. In contrast to cases with negative
PRO2000/ANCCA, p53 and p21WAF1/Cip1 were expressedFigure 4 Immunohistochemical staining of P53 and p21WAF1/Cip1 in co
immunohistochemically stained with (A) anti-P53 and (B) anti-P21 antibodin 72.4% and 79.3% in HCC. PRO2000/ANCCA expression
was not significantly correlated with p53 and p21WAF1/Cip1
(Table 3).
Discussion
PRO2000/ANCCA which located within a region of
chromosome 8q was firstly reported to be an important
candidate gene in HCC [3]. To our knowledge, investi-
gation on biological function of PRO2000/ANCCA in
HCC has not been reported. In this study, we firstly
performed immunohistochemisty method to examine
PRO2000/ANCCA expression in 107 cases of human
HCC along with corresponding non-tumor tissues. The
results showed that PRO2000/ANCCA protein was overex-
pressed in the majority of cancer cells comparing with sur-
rounding hepatocytes. Our data are consistent with the
preliminary report by Crawley et al. using comparative gen-
omic microarray analysis. Of 107 HCC specimens, 61.68%
were demonstrated positive staining for PRO2000/ANCCA,
while 7.48% (8/107) in adjacent non-tumor tissues. There
was a statistical difference of PRO2000/ANCCA expres-
sion in HCC and that in adjacent non-tumor tissues.
The intensity of PRO2000/ANCCA expression in tumor
cells was stronger than that in non-tumor cells. This re-
sult therefore supports the view that PRO2000/ANCCA
may have specific function in malignant differentiation
and proliferation of hepatocytes.
Our data also provided new insights regarding the
relationship between PRO2000/ANCCA expression and
clinicopathological features in HCC. There was a
statistical difference of PRO2000/ANCCA expression in
well differentiated tumors and that in poorly differenti-
ated tumors (P < 0.05). Thus, level of PRO2000/ANCCA
expression was significantly correlated with more aggres-
sive tumor features such as number of tumor nodules,
portal vein invasion, tumor microsatellite formation and
TNM stage. Our study showed that PRO2000/ANCCA-
positive cases had less survival rate than those in
PRO2000/ANCCA-negative cases. These data suggest thatnsecutive sections of an HCC tissue. Tissue sections were
ies. Scale bars = 50 μm.
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predictor for progression and poor prognosis.
PRO2000/ANCCA protein has been reported to be as-
sociated directly with estrogen-bound estrogen receptor
α (ERα) and to mediate E2-stimulated expression of key
cell cycle regulators likely via its ATP-driven protein
complex remodeling function in breast cancer [7]. In this
study, we observed the expression of PRO2000/ANCCA,
Ki-67 and Cyclin D1 in series of sections and found these
proteins were expressed in same cancer cell nucleus. Our
results showed that PRO2000/ANCCA was strongly posi-
tive associated with ki-67 and cyclin D1 in HCC. As a
proliferation-associated nuclear antigen, Ki-67 is present
in cells that are replicating in the G1, S, G2, and M stages
of the cell cycle [14]. Cyclin D1 functions as a regulatory
subunit of CDK4 or CDK6, whose activity is required for
cell cycle G1/S transition [15]. This finding might support
the hypothesis that PRO2000/ANCCA may be involved in
the regulation of proliferation in HCC.
The p53 tumor-suppressor gene has been shown to
play a key role in the control of the cell cycle, cell differ-
entiation and apoptosis. P21WAF1/Cip1, an inhibitor of
cyclin-dependent kinases, is activated through p53-
dependent or p53-independent pathway and plays an
important role in regulation of the cell cycle, especially
in G1 arrest [15-22]. Many studies have demonstrated
that P53 and P21WAF1/Cip1 are involved in carcinogen-
esis of hepatocytes [23-25]. According to our results
stated above, we are also interested in the relationship
between PRO2000/ANCCA and p53 or P21WAF1/Cip1. In
the present study, PRO2000/ANCCA expression was
not consistent with p53 or P21WAF1/Cip1 in cancer cells
within individual tumor. There was not any correlation
between PRO2000/ANCCA and p53 or P21WAF1/Cip1.
These results suggest that PRO2000/ANCCA might
promote cell proliferation in HCC through a p53/
P21WAF1/Cip1-independent pathway.
In summary, this study demonstrated that PRO2000/
ANCCA was overexpressed in HCC and was associated
with clinicopathological features such as number of
tumor nodules, TNM stage, tumor microsatellite, portal
vein tumor thrombus and recurrence, but not with gen-
der, age, cirrhosis, HBV infection and serum AFP level.
There was a strong positive correlation between PRO2000/
ANCCA expression and ki-67 and cyclin D1 but not p53
and p21. Our findings suggested that PRO2000/ANCCA
may be involved in cell cycle regulation in the pathogenesis
of HCC and serves as a predictor for poor prognosis of
HCC. PRO2000/ANCCA might be a candidate gene for
the development of diagnostic and therapeutic strat-
egies for HCC. Further molecular, cellular and animal
model studies are necessary to better understand the
function of PRO2000/ANCCA as the present clinical
samples study.Abbreviations
HCC: Hepatocellular carcinoma; AFP: Alpha fetal protein; ANCCA: AAA
nuclear coregulator cancer-associated protein.
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